RT Journal Article
SR Electronic
T1 Integrated Treatment With Stapled Haemorrhoidopexy and Proctonorm® of Haemorrhoidal Disease
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1671
OP 1675
DO 10.21873/invivo.11654
VO 33
IS 5
A1 GIULIANO REBOA
A1 MARCO GIPPONI
A1 PIERO FREGATTI
A1 FRANCESCA DEPAOLI
YR 2019
UL http://iv.iiarjournals.org/content/33/5/1671.abstract
AB Background/Aim: This retrospective study was performed in patients undergoing Stapled Haemorrhoidopexy (SH) who were post-operatively treated with Proctonorm® with the aim of assessing its effect on early and late haemorrhoidal-related symptoms. Patients and Methods: Forty-six males and 54 females received Proctonorm® (one tablet twice daily for 14 days) and Ketoprofene R (200 mg, one tablet twice daily, as requested). Results: “Early Complication Score” (0-12) two days after surgery was 2.02±1.03; pain VAS (Visual Analogue Scale) (0-10) was 1.21±0.89, and the number of anti-inflammatory tablets was 4.24±1.06. At 40-day post-operative assessment, seven patients had post-operative complications with “Late Complication Score” (0-20) of 0.34±0.68. At six-month follow-up, a high index of patient satisfaction (VAS=9.39±0.24) was self-reported with 75% reduction in CSS (Constipation Scoring System) (1.95±2.58) compared to preoperative scores; “Late Complication Score” was 0. Conclusion: The specific target activity of Proctonorm® at the microcircular level may be effective in patients undergoing SH in order to reduce the inflammatory response of residual haemorrhoids while waiting for stable resolution of symptoms within one or two weeks.